P2RY12 and COVID-19: An open-label, bayesian, adaptive randomized clinical trial was designed to evaluate the benefits and risks of adding a P2Y12 ADPRB (ticagrelor/clopidogrel) to anticoagulant treatment among non-critically ill patients hospitalized for COVID-19.